Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment*Jean‐Louis Vincent, Jonathan Janes, Christian Putensen et al.|Critical Care Medicine|2005Cited by 321
Use of an integrated clinical trial database to evaluate the effect of timing of drotrecogin alfa (activated) treatment in severe sepsisJean‐Louis Vincent, David P. Sundin, James M. O’Brien et al.|Critical Care|2006Cited by 41